Pharmacists should counsel users of medical cannabis,but should they be dispensing it?

Government of Canada. Market data. 2018. Available: https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html (accessed May 9, 2018).

Canadian Pharmacists Association. Medical marijuana. 2016. Available: https://www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-issues/CPhAPosition_MedicalMarijuana.pdf (accessed May 9, 2018).

KPMG. Improving medical marijuana management in Canada. Toronto, 2016. Available: https://www.pharmacists.ca/cpha-ca/assets/File/cpha-on-the-issues/March2016_Improving_Medical_Marijuana_Management_in_Canada_vf.pdf (accessed May 9, 2018).

Anderson G Chan L. Pharmacokinetic drug interactions with tobacco, cannabinoids and smoking cessation products. Clin Pharmacokinet 2016;55(11): 1353-68.

Walsh Z Callaway R Belle-Isle L et al . Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy 2013;24(6):511-6.

Walsh Z Gonzalez R Crosby K et al . Medical cannabis and mental health: a guided systematic review. Clin Psychol Rev 2017;51:15-29.

Lucas P Walsh Z. Medical cannabis access, use, and substitution for prescription opioids and other substances: a survey of authorized medical cannabis patients. Int J Drug Policy 2017;42:30-5.

National Academies of Sciences, Engineering, Medicine. Health effects of cannabis and cannabinoids: current state of evidence and recommendations for research. 2017. Available: http://nationalacademies.org/hmd/~/media/Files/Report%20Files/2017/Cannabis-Health-Effects/Cannabis-public-release-slides.pdf (accessed May 30, 2018).

Packer NG McRae AD Wang D. Cannabis hyperemesis syndrome within emergency department users in the Calgary health region: a retrospective analysis. Can J Emerg Med 2018;20(Suppl 1):S95-S95.

Lapoint J Meyer S Yu CK et al . Cannabinoid hyperemesis syndrome: public health implications and a novel model treatment guideline. West J Emerg Med 2018;19(2):380-6.

Hall W Degenhardt L. Adverse health effects of non-medical cannabis use. Lancet 2009;374(9698):1383-91.

Martins SS Gorelick DA. Conditional substance abuse and dependence by diagnosis of mood or anxiety disorder or schizophrenia in the US population. Drug Alcohol Depend 2011;119(1-2):28-36.

Volkow ND Baler RD Compton WM Weiss SRB . Adverse health effects of marijuana use. N Engl J Med 2014;370(23):2219-27.

Viveros M Llorente R Suarez J et al . The endocannabinoid system in critical neurodevelopmental periods: sex differences and neuropsychiatric implications. J Psychopharmacol 2012;26(1):164-76.

Stefanis NC Delespaul P Henquet C et al . Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 2004;99(10):1333-41.

Newcomb M Bentler P. Consequences of adolescent drug use: impact on the lives of young adults. Thousand Oaks (CA): Sage; 1988.

Duncan SC Duncan TE Biglan A Ary D. Contributions of the social context to the development of adolescent substance use: a multivariate latent growth modeling approach. Drug Alcohol Depend 1998;50(1):57-71.

Belle-Isle L Walsh Z Callaway R et al . Barriers to access for Canadians who use cannabis for therapeutic purposes. Int J Drug Policy 2014;25(4):691-9.

Statistics Canada. Cannabis stats hub. 2018. Available: https://www.statcan.gc.ca/pub/13-610-x/cannabis-eng.htm (accessed May 9, 2018).

Statistics Canada. Canadian Tobacco, Alcohol and Drugs Survey. 2017. Available: https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcohol-drugs-survey.html (accessed May 9, 2018).

Capler R Walsh Z Crosby K et al . Are dispensaries indispensable? Patient experiences of access to cannabis from medical cannabis dispensaries in Canada. Int J Drug Policy 2017;47:1-8.

Teotonio I . Private Insurer covers medical marijuana costs. 2015. Available: https://www.thestar.com/life/health_wellness/2015/03/20/private-insurer-covers-medical-marijuana-costs.html (accessed May 9, 2018).

Manion Wilkins . Dispensing fee report—all provinces except ON. 2017. Available: www.manionwilkins.com/wp-content/uploads/2017/11/Quarterly-Disp-Fee-Rpt_with-DA-COB-claims-ESC-BOB-Q3-2017-All-Provinces-except-Ontario-wdc.pdf (accessed May 9, 2018).

Ligaya A . Ottawa’s plan for excise tax on medical marijuana draws ire of patients, producers. 2017. Available: https://www.ctvnews.ca/health/ottawa-s-plan-for-excise-tax-on-medical-marijuana-draws-ire-of-patients-producers-1.3672704 (accessed May 9, 2018).

Wong L Burden AM Liu YY et al . Initial uptake of the Ontario pharmacy smoking cessation program: descriptive analysis over 2 years. Can Pharm J (Ott) 2015;148(1):29-40.

Brown TJ Todd A O’Malley C et al . Community pharmacy-delivered interventions for public health priorities: a systematic review of interventions for alcohol reduction, smoking cessation and weight management, including meta-analysis for smoking cessation. BMJ Open 2016;6(2):e009828.